- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study2017 | 1. lékařská fakulta
- Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy2017 | 1. lékařská fakulta
- Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months2016 | 1. lékařská fakulta
- Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings2017 | 1. lékařská fakulta
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | 1. lékařská fakulta